Traws Pharma, Inc. /
Viriom
Traws Pharma purchases antiviral program assets from Viriom, Inc.
Source for the buyer and target: Traws Pharma, Inc.
For the buyer and target.
“On September 9, 2025, Traws Pharma, Inc. (the “Company”) and Virom, Inc. (“Viriom”) entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company purchased certain assets (the “Purchased Assets”) from Viriom in exchange for $2,350,000 in cash (the “Purchase Price”), which was paid in full to Virom on September 9, 2025.”
Published 12 Sep 2025
Open the sourceWhat happened
Traws Pharma, Inc. purchased certain assets from Viriom, Inc. for $2,350,000 in cash, paid in full on Sept. 9, 2025. [01]
The assets include intellectual property, a program pipeline and related rights for a pyrrolidine antiviral compound. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Traws Pharma purchases antiviral program assets from Viriom, Inc.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“Traws Pharma purchases antiviral program assets from Viriom, Inc. Traws Pharma, Inc. purchased certain assets from Viriom, Inc. for $2,350,000 in cash, paid in full on Sept. 9, 2025”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly